Key Highlights

  • LifeMD (NASDAQ:LFMD) was trading up 14.5% at USD 1.90 in pre-market on Friday, November 13, 2026, a day after third-quarter results; the implied prior close is about USD 1.66 (calculated).
  • Third-quarter Revenue was USD 44.6 million, down about 7% from USD 47.7 million a year earlier, with a net loss from continuing operations of USD 5.2 million, or USD 0.11 per share.
  • Full-year 2026 revenue guidance was lowered to USD 188 million to USD 191 million from USD 205.5 million to USD 212.5 million, and adjusted EBITDA is now expected to be a loss of USD 10.6 million to USD 12.6 million.
  • Cash was USD 21.9 million at September 30, 2026, and a USD 12.5 million senior secured term Loan with Avenue Capital closed after quarter end.

Pre-Market Bounce Follows a Lower Full-Year Outlook

LifeMD (NASDAQ:LFMD) reported third-quarter 2026 results on November 12, 2026, and shares were indicated higher in pre-market on Friday. The pre-market quote is the figure of record here, and a move of this size in a sub-USD 5 stock can reverse. Revenue of USD 44.6 million fell about 7% year over year, and gross Margin eased to about 82% from 85% a year earlier. The company lowered its 2026 revenue outlook by about USD 19.5 million at the midpoint (calculated from the old and new ranges). It guided fourth-quarter revenue to USD 46 million to USD 49 million, with adjusted EBITDA of negative USD 4 million to negative USD 2 million. The prior full-year adjusted EBITDA range was a loss of USD 6.0 million to breakeven, so the new loss range is wider.

Cost Cuts and Subscriber Growth Offset Falling Sales

LifeMD describes itself as a virtual primary care and pharmacy company serving more than 200 conditions, including weight management and hormone therapy. Selling and Marketing expense fell 34% from the second quarter to USD 18.5 million, which helped narrow the adjusted EBITDA loss to about USD 0.4 million from USD 3.5 million in the second quarter. Active subscribers reached about 350,000, up 13% from about 310,818, and pharmacy shipment Volume rose 58.3%. The pharmacy has started dispensing self-pay branded GLP-1 medicines under arrangements with Novo Nordisk and Eli Lilly.

Thin Cash Cushion and Execution Risk After the Reset

Balance sheet room is limited. Cash of USD 21.9 million sat against no Debt at quarter end, but the new USD 12.5 million term loan adds fixed obligations and replaces the revolving facility. General and administrative expense rose 6% year over year to USD 14.7 million while sales fell. An exclusive arrangement with AT&T gives access to about 100 million wireless and fiber customers and 110,000 employees, and the enterprise offering starts marketing in the fourth quarter. The risk is that guidance already fell once this year, so a further miss could erase the bounce. The company did not give a single reason for the share price reaction, so the rebound is best read as a market response to the results and lowered expectations.

Where Things Stand

The stock is rising because investors appear to be reading the cost cuts, a narrower adjusted EBITDA loss and a clearer fourth-quarter range as a reset, even though revenue guidance fell. LifeMD (NASDAQ:LFMD) still posted a net loss, shrinking sales and a modest cash balance. Next markers are the fourth-quarter revenue range of USD 46 million to USD 49 million, enterprise marketing results and any further financing steps. Investors will also watch gross margin, which slipped from 89% in the second quarter.